InnoCare Pharma Ltd
688428
Company Profile
Business description
InnoCare Pharma Ltd is a commercial-stage biopharmaceutical company. It discovers, develops, and commercializes drugs for the treatment of cancer and autoimmune diseases. The company's main product pipeline includes orelabrutinib, ibrutinib, zanubrutinib, tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-192, ICP-723, and ICP-189, among others. Its products are mainly used to treat hematological tumors, solid tumors, and autoimmune diseases. The company is also developing products for the treatment of autoimmune diseases caused by abnormal B-cell or T-cell function.
Contact
No. 8 Life Science Park Road
Building 8, Zhongguancun Life Science Park
Changping District
Beijing102206
CHNT: +86 1066609999
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
1,176
Stocks News & Analysis
stocks
Are small caps finally back?
Does renewed investor interest point to a structural shift in the underperforming factor?
stocks
Chart of the Week: Modest earnings growth at odds with overvalued bank shares
The latest update from our Industry Pulse report.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,329.10 | 50.90 | 0.55% |
| CAC 40 | 8,225.78 | 18.91 | 0.23% |
| DAX 40 | 24,207.79 | 56.66 | 0.23% |
| Dow JONES (US) | 46,705.77 | 115.36 | 0.25% |
| FTSE 100 | 9,578.57 | 63.57 | 0.67% |
| HKSE | 25,967.98 | 186.21 | 0.72% |
| NASDAQ | 22,926.81 | 186.41 | 0.82% |
| Nikkei 225 | 48,641.61 | 666.18 | -1.35% |
| NZX 50 Index | 13,377.10 | 70.66 | 0.53% |
| S&P 500 | 6,735.30 | 35.90 | 0.54% |
| S&P/ASX 200 | 9,032.80 | 46.60 | 0.52% |
| SSE Composite Index | 3,922.41 | 8.65 | 0.22% |